Results for tag: "Warm Autoimmune Hemolytic Anemia Drug"

Warm Autoimmune Hemolytic Anemia (WAIHA) is a rare type of anemia caused by an autoimmune disorder. It is characterized by the destruction of red blood cells by the body's own immune system. Treatment for WAIHA typically involves the use of hematological drugs, such as corticosteroids, immunosuppressants, and monoclonal antibodies. These drugs are used to reduce the production of antibodies that attack red blood cells, as well as to reduce inflammation and suppress the immune system. In some cases, blood transfusions may also be necessary. The WAIHA drug market is a small but growing segment of the hematological drugs market. It is driven by the increasing prevalence of WAIHA, as well as the development of new drugs and treatments. Companies in this market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more